Extracellular nucleic acids in maternal circulation as potential biomarkers for placental insufficiency

DNA and Cell Biology

Volumn 31, Issue 7, 2012, Pages 1221-1232

  Hromadnikova, Ilona ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; MESSENGER RNA; NUCLEIC ACID;

ALGORITHM; APOPTOSIS; ARTICLE; CIRCULATION; DIAGNOSTIC PROCEDURE; HUMAN; MATERNAL CIRCULATION; MATERNAL WELFARE; PLACENTA INSUFFICIENCY; PREDICTION; PREECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATION; PRIORITY JOURNAL; TROPHOBLAST;

BIOLOGICAL MARKERS; DNA; EXTRACELLULAR SPACE; FEMALE; HUMANS; MOTHERS; PLACENTAL INSUFFICIENCY; PREGNANCY; RNA;

EID: 84863907845     PISSN: 10445498     EISSN: 15577430     Source Type: Journal    
DOI: 10.1089/dna.2011.1530     Document Type: Article

References (98)

1. ACOG Committee on Practice Bulletins-Obstetrics. (2002). Diagnosis and management of preeclampsia and eclampsia. Obstet Gynecol 99, 159-167.
2. Akolekar, R., Minekawa, R., Veduta, A., Romero, X.C., and Nicolaides, K.H. (2009). Maternal plasma inhibin A at 11-13 weeks of gestation in hypertensive disorders of pregnancy. Prenat Diagn 29, 753-760.
3. Akolekar, R., Syngelaki, A., Sarquis, R., Zvanca, M., and Nicolaides, K.H. (2011). Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11-13 weeks. Prenat Diagn 31, 66-74.
4. Alberry, M.S., Maddocks, D.G., Hadi, M.A., Metawi, H., Hunt, L.P., Abdel-Fattah, S.A., Avent, N.D., and Soothill, P.W. (2009). Quantification of cell free fetal DNA in maternal plasma in normal pregnancies and in pregnancies with placental dysfunction. Am J Obstet Gynecol 2009, 98.e1-98.e6.
5. Anderson, U.D., Olsson, M.G., Kristensen, K.H., Akerström, B., and Hansson, S.R. (2011). Review: Biochemical markers to predict preeclampsia. Placenta 33 Suppl, S42-S47.
6. Ason, B., Darnell, D.K., Wittbrodt, B., Berezikov, E., Kloosterman, W.P., Wittbrodt, J., Antin, P.B., and Plasterk, R.H. (2006). Differences in vertebrate microRNA expression. Proc Natl Acad Sci U S A 103, 14385-14389.
7. Aspirin and pre-eclampsia. (1986). Lancet 1, 328-329.
8. Baehrecke, E.H. (2003). miRNAs: Micro managers of programmed cell death. Curr Biol 13, R473-R475.
9. Bartel, D.P. (2004). MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 116, 281-297.
10. Beta, J., Akolekar, R., Ventura, W., Syngelaki, A., and Nicolaides, K.H. (2011). Prediction of spontaneous preterm delivery from maternal factors, obstetric history and placental perfusion and function at 11-13 weeks. Prenat Diagn 31, 75-83.
11. Brennecke, J., Hipfner, D.R., Stark, A., Russell, R.B., and Cohen, S.M. (2003). Bantam encodes a developmentally regulated microRNA that controls cell proliferation and regulates the proapoptotic gene hid in Drosophila. Cell 113, 25-36.
12. Bujold, E., Roberge, S., Lacasse, Y., Bureau, M., Audibert, F., Marcoux, S., Forest, J.C., and Giguere, Y. (2010). Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: A meta-analysis. Obstet Gynecol 116, 402-414.
13. Calin, G.A., and Croce, M.C. (2006). MicroRNA signatures in human cancers. Nat Rev Cancer 6, 857-866.
14. Caramelli, E., Rizzo, N., Concu, M., Simonazzi, G., Carinci, P., Bondavalli, C., Bovicelli, L., and Farina, A. (2003). Cell-free fetal DNA concentration in plasma of patients with abnormal uterine artery Doppler waveform and intrauterine growth restriction-a pilot study. Prenatal Diagn 23, 367-371.
15. Chan, K.C., Ding, C., Gerovassili, A., Yeung, S.W., Chiu, R.W., Leung, T.N., Lau, T.K., Chim, S.S., Chung, G.T., Nicolaides, K.H., and Lo, Y.M. (2006). Hypermethylated RASSF1A in maternal plasma: A universal fetal DNA marker that improves the reliability of noninvasive prenatal diagnosis. Clin Chem 52, 2211-2218.
16. Chan, K.C., Zhang, J., Hui, A.B., Wong, N., Lau, T.K., Leung, T.N., Lo, K.W., Huang, D.W., and Lo, Y.M. (2004). Size distributions of maternal and fetal DNA in maternal plasma. Clin Chem 50, 88-92.
17. Chim, S.S., Shing, T.K., Hung, E.C., Leung, T.Y., Lau, T.K., Chiu, R.W., and Lo, Y.M. (2008). Detection and characterization of placental microRNAs in maternal plasma. Clin Chem 54, 482-490.
18. Cotter, A.M., Martin, C.M., O'leary, J.J., and Daly, S.F. (2004). Increased fetal DNA in the maternal circulation in early pregnancy is associated with an increased risk of preeclampsia. Am J Obstet Gynecol 191, 515-520.
19. Department of Biological Science and Technology, Institute of Bioinformatics National Chiao Tung University, Hsinchu, Taiwan. (2011). Available at http://mirnamap.mbc.nctu .edu.tw/
20. De Vivo, A., Baviera, G., Giordano, D., Todarello, G., Corrado, F., and D'anna, R. (2008). Endoglin, PlGF and sFlt-1 as markers for predicting pre-eclampsia. Acta Obstet Gynecol Scand 87, 837-842.
21. Engel, K., P1onka, T., Bilar, M., Czajkowska, E., Orziń ska, E., Brojer, E., and Ronin-Walknowska, E. (2007). The analysis of the correlation between extracellular fetal DNA concentration in maternal circulation and severity of preeclampsia. Ann Acad Med Stetin 53, 20-25.
22. Enquobahrie, D.A., Abetew, D.F., Sorensen, T.K., Willoughby, D., Chidambaram, K., and Williams, M.A. (2011). Placental microRNA expression in pregnancies complicated by preeclampsia. Am J Obstet Gynecol 204, 178.e12-178.e21.
23. Farina, A., Chan, C.W.M., Chiu, R.W.K., Tsui, N.B.Y., Carinci, P., Concu, M., Banzola, I., Rizzo, N., and Lo, Y.M.D. (2004a). Circulating corticotropin-releasing hormone mRNA in maternal plasma: Relationship with gestational age and severity of preeclampsia. Clin Chem 50, 1851-1854.
24. Farina, A., Sekizawa, A., Purwosunu, Y., Rizzo, N., Banzola, I., Concu, M., et al. (2006). Quantitative distribution of a panel of circulating mRNA in preeclampsia versus controls. Prenat Diagn 26, 1115-1120.
25. Farina, A., Sekizawa, A., Rizzo, N., Concu, M., Banzola, I., Carinci, P., Simonazzi, G., and Okai, T. (2004b). Cell-free fetal DNA (SRY locus) concentration in maternal plasma is directly correlated to the time elapsed from the onset of preeclampsia to the collection of blood. Prenat Diagn 24, 293-297.
26. Farina, A., Sekizawa, A., Sugito, Y., Iwasaki, M., Jimbo, M., Saito, H., and Okai, T. (2004c). Fetal DNA in maternal plasma as a screening variable for preeclampsia. Prenat Diagn 24, 83-86.
27. Fujito, N., Samura, O., Miharu, N., Tanigawa, M., Hyodo, M., and Kudo, Y. (2006). Increased plasma mRNAs of placentaspecific 1 (PLAC1) and glial cells-missing 1 (GCM1) in mothers with pre-eclampsia. Hiroshima J Med Sci 55, 9-15.
28. Galbiati, S., Causarano, V., Pinzani, P., Francesca, S., Orlando, C., Smid, M., Pasi, F., Castiglioni, M.T., Cavoretto, P., Rovere-Querini, P., Pedroni, S., Calza, S., Ferrari, M., and Cremonesi, L. (2010). Evaluation of a panel of circulating DNA, RNA and protein potential markers for pathologies of pregnancy. Clin Chem Lab Med 48, 791-794.
29. Gilad, S., Meiri, E., Yogev, Y., Benjamin, S., Lebanony, D., Yerushalmi, N., Benjamin, H., Kushnir, M., Cholakh, H., Melamed, N., Bentwich, Z., Hod, M., Goren, Y., and Chajut, A. (2008). Serum microRNAs are promising novel biomarkers. PLoS One 3, e3148.
30. Goetzinger, K.R., Singla, A., Gerkowicz, S., Dicke, J.M., Gray, D.L., and Odibo, A.O. (2010). Predicting the risk of preeclampsia between 11 and 13 weeks'gestation by combining maternal characteristics and serum analytes, PAPP-A and free b-hCG. Prenat Diagn 30, 1138-1142.
31. Gunawardana, L., Zammit, S., Lewis, G., Gunnell, D., Hollis, C., Wolke, D., and Harrison, G. (2011). Examining the association between maternal analgesic use during pregnancy and risk of psychotic symptoms during adolescence. Schizophr Res 126, 220-225.
32. Hromadnikova, I., Benesova, M., and Zejskova, L. (2009). The effect of DYS-14 copy number variations on extracellular fetal DNA quantification in maternal circulation. DNA Cell Biol 28, 351-358.
33. Hromadnikova, I., Kotlabova, K., Doucha, J., and Dlouha, K. (2011a). Absolute and relative quantification of placental specific microRNAs in maternal circulation with placental insufficiency related complications. Abstract no. ID109, presented at the 5th International qPCR Symposium, Freising, Germany, March 28-April 1.
34. Hromadnikova, I., Kotlabova, K., Doucha, J., and Dlouha, K. (2011b). Absolute and relative quantification of placental specific microRNAs in maternal circulation with placental insufficiency related complications. Abstract no. OP06.10, presented at the 21st World Congress on Ultrasound in Obstetrics and Gynecology (ISUOG), Los Angeles, CA, September 18-22.
35. Hromadnikova, I., Kotlabova, K., Doucha, J., and Dlouha, K. (2011c). Absolute and relative quantification of placental specific microRNAs in maternal circulation with placental insufficiency related complications. Abstract no. 17, presented at the 15th World Congress on Controversies in Obstetrics, Gynecology and Infertility (COGI), Sanya Hainan, China, December 8-11.
36. Hromadnikova, I., Kotlabova, K., Doucha, J., Dlouha, K., and Krofta, L. (2012). Absolute and relative quantification of placental specific microRNAs in maternal circulation with placental insufficiency related complications. J Mol Diagn 14, 160-167.
37. Hromadnikova, I., Kotlabová , K., Jirásek, J.E., and Doucha, J. (2010a). Detection of placenta-specific microRNAs in maternal circulation. Ceska Gynekol 75, 252-256.
38. Hromadnikova, I., Zejskova, L., Kotlabova, K., Jancuskova, T., Doucha, J., Dlouha, K., et al. (2010b). Quantification of extracellular DNA using hypermethylated RASSF1A, SRY, and GLO sequences-evaluation of diagnostic possibilities for predicting placental insufficiency. DNA Cell Biol 29, 295-301.
39. Hu, Z.Y., Liu, Y.X., Liu, K., Byrne, S., Ny, T., Feng, Q., and Ockleford, C.D. (1999). Expression of tissue type and urokinase type plasminogen activators as well as plasminogen activator inhibitor type-1 and type-2 in human and rhesus monkey placenta. J Anat 194, 183-195.
40. Huppertz, B. (2008). Placental origins of preeclampsia: Challenging the current hypothesis. Hypertension 51, 970-975.
41. Huppertz, B., and Kingdom, J.C. (2004). Apoptosis in the trophoblast-role of apoptosis in placental morphogenesis. J Soc Gynecol Investig 11, 353-362.
42. Illanes, S., Parra, M., Serra, R., Pino, K., Fiquerosa-Diesel, H., Romero, C., Arraztoa, J.A., Michea, L., and Soothill, P.W. (2009). Increased free fetal DNA levels in early pregnancy plasma of women who subsequently develop preeclampsia and intrauterine growth restriction. Prenat Diagn 29, 1118-1122.
43. Karagiannis, G., Akolekar, R., Sarquis, R., Wright, D., and Nicolaides, K.H. (2011). Prediction of small-for-gestation neonates from biophysical and biochemical markers at 11-13 weeks. Fetal Diagn Ther 29, 148-154.
44. Khan, K.S., Wojdyla, D., Say, L., Gülmezoglu, A.M., and Van Look, P.F. (2006). WHO analysis of causes of maternal death: A systematic review. Lancet 367, 1066-1074.
45. Khong, T.Y., De Wolf, F., Robertson, W.B., and Brosens, I. (1986). Inadequate maternal vascular response to placentation in pregnancies complicated by pre-eclampsia and by small-for-gestational age infants. Br J Obstet Gynaecol 93, 1049-1059.
46. Khvorova, A., Reynolds, A., and Jayasena, S.D. (2003). Functional siRNAs and miRNAs exhibit strand bias. Cell 115, 209-216.
47. Kloosterman, W.P., and Plasterk, R.H. (2006). The diverse functions of microRNAs in animal development and disease. Dev Cell 11, 441-450.
48. Kotlabova, K., Doucha, J., and Hromadnikova, I. (2011). Placentalspecific microRNA in maternal circulation-identification of appropriate pregnancy associated microRNAs with diagnostic potential. J Rep Imunol 89, 185-191.
49. Lai, E.C. (2002). MicroRNAs are complementary to 3¢UTR sequence motifs that mediate negative post-transcriptional regulation. Nat Genet 23, 175-205.
50. Lau, T.W., Leung, T.N., Chan, L.Y., Lau, T.K., Chan, K.C., Tam, W.H., and Lo, Y.M. (2002). Fetal DNA clearance from maternal plasma is impaired in preeclampsia. Clin Chem 48, 2141-2146.
51. Leung, T.N., Zhang, J., Lau, T.K., Chan, L.Y., and Lo, Y.M. (2001). Increased maternal plasma fetal DNA concentrations in women who eventually develop preeclampsia. Clin Chem 47, 137-139.
52. Levine, R.J., Qian, C., Leshane, E.S., Yu, K.F., England, L.J., Schisterman, E.F., Wataganara, T., Romero, R., and Bianchi, D.W. (2004). Two-stage elevation of cell-free fetal DNA in maternal sera before onset of preeclampsia. Am J Obstet Gynecol 190, 707-713.
53. Li, Y., Zimmermann, B., Rusterholz, C., Kang, A., Holzgreve, W., and Hahn, S. (2004). Size separation of circulatory DNA in maternal plasma permits ready detection of fetal DNA polymorphisms. Clin Chem 50, 1002-1011.
54. Liang, Y., Ridzon, D., Wong, L., and Chen, C. (2007). Characterization of microRNA expression profiles in normal human tissues. BMC Genomics 8, 166.
55. Lo, Y.M., Corbetta, N., Chamberlain, P.F., Rai, V., Sargent, I.L., Redman, C.W., and Wainscoat, J.S. (1997). Presence of fetal DNA in maternal plasma and serum. Lancet 350, 485-487.
56. Lo, Y.M., Leung, T.N., Tein, M.S., Sargent, I.L., Zhang, J., Lau, T.K., Haines, C.J., and Redman, C.W. (1999). Quantitative abnormalities of fetal DNA in maternal serum in preeclampsia. Clin Chem 45, 184-188.
57. Lo, Y.M., Tein, M.S., Lau, T.K., Haines, C.J., Leung, T.N., Poon, P.M., Wainscoat, J.S., Johnson, P.J., Chang, A.M., and Hjelm, N.M. (1998). Quantitative analysis of fetal DNA in maternal plasma and serum: Implications for noninvasive prenatal diagnosis. Am J Hum Genet 62, 768-775.
58. Lo, Y.M.D., Chiu, R.W.K., Chim, S.S.C., Ding, C., Chan, K.C., Wong, H.N.I., and Yuen, K.C.R. (2007). New fetal methylation markers. WO2007132166.
59. Lo, Y.M.D., Chiu, R.W.K., Chim, S.S.C., Ding, C., Chan, K.C., Wong, H.N.I., and Yuen, K.C.R. (2009). Fetal methylation markers. US20090155776.
60. Martinhago, C.D., De Oliveira, R.M., Tomitão Canas Mdo, C., Vagnini, L.D., Alcantara Oliveira, J.B., Petersen, C.G., and Franco Junior, J.G. (2006). Accuracy of fetal gender determination in maternal plasma at 5 and 6 weeks of pregnancy. Prenat Diagn 26, 1219-1223.
61. Mayor-Lynn, K., Toloubeydokhti, T., Cruz, A.C., and Chegini, N. (2011). Expression profile of microRNAs and mRNAs in human placentas from pregnancies complicated by preeclampsia and preterm labor. Reprod Sci 18, 46-56.
62. Mikat, B., Zeller, A., Scherag, A., Drommelschmidt, K., Kimmig, R., and Schmidt, M. (2011). bhCG and PAPP-A in first trimester: Predictive factors for preeclampsia? Hypertens Pregnancy 2011 Dec 9. [Epub ahead of print] DOI: 10.3109/10641955.2011.638956
63. Miura, K., Miura, S., Yamasaki, K., Higashijima, A., Kinoshita, A., Yoshiura, K., and Masuzaki, H. (2010). Identification of pregnancy-associated microRNAs in maternal plasma. Clin Chem 56, 1767-1771.
64. Nelson, D.M. (1996). Apoptotic changes occur in syncytiotrophoblast of human placental villi where fibrin type fibrinoid is deposited at discontinuities in the villous trophoblast. Placenta 17, 387-391.
65. Ng, E.K., Leung, T.N., Tsui, N.B., Lau, T.K., Panesar, N.S., Chiu, R.W., and Lo, Y.M. (2003a). The concentration of circulating corticotropin-releasing hormone mRNA in maternal plasma is increased in preeclampsia. Clin Chem 49, 727-731.
66. Ng, E.K., Tsui, N.B., Lau, T.K., Leung, T.N., Chiu, R.W., Panesar, N.S., Lit, L.C., Chan, K.W., and Lo, Y.M. (2003b). mRNA of placental origin is readily detectable in maternal plasma. Proc Natl Acad Sci U S A 100, 4748-4753.
67. Noack, F., Ribbat-Idel, J., Thorns, C., Chiriac, A., Axt-Fliedner, R., Diedrich, K., and Feller, A.C. (2011). miRNA expression profiling in formalin-fixed and paraffin-embedded placental tissue samples from pregnancies with severe preeclampsia. J Perinat Med 39, 267-271.
68. Orozco, A.F., Bischoff, F.Z., Horne, C., Popek, E., Simpson, J.L., and Lewis, D.E. (2006). Hypoxia-induced membrane-bound apoptotic DNA particles: Potential mechanism of fetal DNA in maternal plasma. Ann N Y Acad Sci 1075, 57-62.
69. Oudejans, C.B., Tjoa, M.L., Westerman, B.A., Mulders, M.A., Van Wijk, I.J., and Van Vugt, J.M. (2003). Circulating trophoblast in maternal blood. Prenat Diagn 23, 111-116.
70. Pang, W.W., Tsui, M.H., Sahota, D., Leung, T.Y., Lau, T.K., Lo, Y.M., and Chiu, R.W. (2009). A strategy for identifying circulating placental RNA markers for fetal growth assessment. Prenat Diagn 29, 495-504.
71. Pineles, B.L., Romero, R., Montenegro, D., Tarca, A.L., Han, Y.M., Kim, Y.M., Draghici, S., Espinoza, J., Kusanovic, J.P., Mittal, P., Hassan, S.S., and Kim, C.J. (2007). Distinct subset of microRNAs are expressed differentially in the human placentas of patients with preeclampsia. Am J Obstet Gynecol 196, 261.e1-261.e6.
72. Poon, L.C., Akolekar, R., Lachmann, R., Beta, J., and Nicolaides, K.H. (2010a). Hypertensive disorders in pregnancy: Screening by biophysical and biochemical markers at 11-13 weeks. Ultrasound Obstet Gynecol 35, 662-670.
73. Poon, L.C., Kametas, N.A., Chelemen, T., Leal, A., and Nicolaides, K.H. (2010b). Maternal risk factors for hypertensive disorders in pregnancy: A multivariate approach. J Hum Hypertens 24, 104-110.
74. Poon, L.C., Kametas, N.A., Maiz, N., Akolekar, R., and Nicolaides, K.H. (2009). First-trimester prediction of hypertensive disorders in pregnancy. Hypertension 53, 812-818.
75. Purwosunu, Y., Sekizawa, A., Farina, A., Wibowo, N., Koide, K., Okazaki, S., Nakamura, M., and Okai, T. (2008). Evaluation of physiological alterations of the placenta through analysis of cell-free messenger ribonucleic acid concentrations of angiogenic factors. Am J Obstet Gynecol 198, 124.e1-124.e 7.
76. Purwosunu, Y., Sekizawa, A., Farina, A., Wibowo, N., Okazaki, S., Nakamura, M., Samura, O., Fujito, N., and Okai, T. (2007a). Cell-free mRNA concentrations of CRH, PLAC1, and selectin-P are increased in the plasma of pregnant women with preeclampsia. Prenat Diagn 27, 772-777.
77. Purwosunu, Y., Sekizawa, A., Koide, K., Farina, A., Wibowo, N., Wiknjosastro, G.H., Okazaki, S., Chiba, H., and Okai, T. (2007b). Cell-free mRNA concentrations of plasminogen activator inhibitor-1 and tissue-type plasminogen activator are increased in the plasma of pregnant women with preeclampsia. Clin Chem 53, 399-404.
78. Purwosunu, Y., Sekizawa, A., Okazaki, S., Farina, A., Wibowo, N., Nakamura, M., Rizzo, N., Saito, H., and Okai, T. (2009). Prediction of preeclampsia by analysis of cell-free messenger RNA in maternal plasma. Am J Obstet Gynecol 200, 386.e1-386.e7.
79. Reddy, A., Zhong, X.Y., Rusterholz, C., Hahn, S., Holzgreve, W., Redman, C.W., and Sargent, I.L. (2008). The effect of labour and placental separation on the shedding of syncytiotrophoblast microparticles, cell-free DNA and mRNA in normal pregnancy and pre-eclampsia. Placenta 29, 942-949.
80. Rosenfeld, N., Aharonov, R., Meiri, E., Rosenwald, S., Spector, Y., Zepeniuk, M., Benjamin, H., Shabes, N., Tabak, S., Levy, A., Lebanony, D., Goren, Y., Silberschein, E., Targan, N., Ben-Ari, A., Gilad, S., Sion-Vardy, N., Tobar, A., Feinmesser, M., Kharenko, O., Nativ, O., Nass, D., Perelman, M., Yosepovich, A., Shalmon, B., Polak-Charcon, S., Fridman, E., Avniel, A., Bentwich, I., Bentwich, Z., Cohen, D., Chajut, A., and Barshack, I. (2008). MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol 26, 462-469.
81. Schwarz, D.S., Hutvágner, G., Du, T., Xu, Z., Aronin, N., and Zamore, P.D. (2003). Asymmetry in the assembly of the RNAi enzyme complex. Cell 115, 199-208.
82. Sekizawa, A., Jimbo, M., Saito, H., Iwasaki, M., Matsuoka, R., Okai, T., and Farina, A. (2003). Cell-free fetal DNA in plasma of pregnant women with severe fetal growth restriction. Am J Obstet Gynecol 188, 480-484.
83. Sifakis, S., Zaravinos, A., Maiz, N., Spandidos, D.A., and Nicolaides, K.H. (2009). First-trimester maternal plasma cell-free fetal DNA and preeclampsia. Am J Obstet Gynecol 201, 472.e1-472.e7.
84. Smid, M., Vassallo, A., Lagona, F., Valsecchi, L., Maniscalco, L., Danti. L., Lojacono, A., Ferrari, A., Ferrari, M., and Cremonesi, L. (2001). Quantitative analysis of fetal DNA in maternal plasma in pathological conditions associated with placental abnormalities. Ann N Y Acad Sci 945, 132-137.
85. Spencer, K., Cowans, N.J., and Nicolaides, K.H. (2008). Low levels of maternal serum PAPP-A in the first trimester and the risk of pre-eclampsia. Prenat Diagn 28, 7-10.
86. Stirnemann, J., Salomon, L., Benoist, G., Essaoui, M., Bernard, J., and Ville, Y. (2011). Performance of routine screening for preeclampsia by maternal factors, uterine artery Doppler, arterial pressure and PAPP-A in a general population setting. Abstract no. OC03.01, presented at the 21st World Congress on Ultrasound in Obstetrics and Gynecology (ISUOG), Los Angeles, CA, September 18-22.
87. Thorp, J.A., Walsh, S.W., and Brath, P.C. (1988). Low-dose aspirin inhibits thromboxane, but not prostacyclin, production by human placental arteries. Am J Obstet Gynecol 159, 1381-1384.
88. Tsui, D.W., Chan, K.C., Chim, S.S., Chan, L.W., Leung, T.Y., Lau, T.K., Lo, Y.M., and Chiu, R.W. (2007). Quantitative aberrations of hypermethylated RASSF1A gene sequences in maternal plasma in pre-eclampsia. Prenat Diagn 27, 1212-1218.
89. Valensise, H., Vasapollo, B., Gagliardi. G., and Novelli, G.P. (2008). Early and late preeclampsia two different maternal hemodynamic states in the latent phase of the disease. Hypertension 52, 873-880.
90. Verlohren, S., Galindo, A., Schlembach, D., Zeisler, H., Herraiz, I., Moertl, M.G., Pape, J., Dudenhausen, J.W., Denk, B., and Stepan. H. (2010). An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. Am J Obstet Gynecol 202, 161.e1-161.e11.
91. Von Dadelszen, P., Magee, L.A., and Roberts, J.M. (2003). Subclassification of preeclampsia. Hypertens Pregnancy 22, 143-148.
92. Whitley, G.S., Dash, P.R., Ayling, L.J., Prefumo, F., Thilaganathan, B., and Cartwright, J.E. (2007). Increased apoptosis in first trimester extravillous trophoblasts from pregnancies at higher risk of developing preeclampsia. Am J Pathol 170, 1903-1909.
93. WHO. (1988). World Health Organization International Collaborative Study of Hypertensive Disorders in Pregnancy. Geographic variation in the incidence of hypertension in pregnancy. Am J Obstet Gynecol 158, 80-83.
94. Zhang, Y., Fei, M., Xue, G., Zhou, Q., Jia, Y., Li, L., Xin, H., and Sun, S. (2011). Elevated levels of hypoxia-inducible microRNA-210 in preeclampsia: New insights into molecular mechanisms for the disease. J Cell Mol Med 16, 249-259.
95. Zhao, F., Wang, J., Liu, R., Yang, J., Cui, K., Wu, Y., Guo, J., Mu, Y., and Wang, X. (2010). Quantification and application of the placental epigenetic signature of the RASSF1A gene in maternal plasma. Prenat Diagn 30, 778-782.
96. Zhong, X.Y., Laivuori, H., Livingston, J.C., Ylikorkala, O., Sibai, B.M., Holzgreve, W., and Hahn, S. (2001). Elevation of both maternal and fetal extracellular circulating deoxyribonucleic acid concentrations in the plasma of pregnant women with preeclampsia. Am J Obstet Gynecol 184, 414-419.
97. Zhong, X.Y., Volgmann, T., Hahn, S., and Holzgreve, W. (2007). Large scale analysis of circulatory fetal DNA concentrations in pregnancies which subsequently develop preeclampsia using two Y chromosome specific real-time PCR assays. JTTGA 8, 135-139.
98. Zhu, X.M., Han, T., Sargent, I.L., Yin, G.W., and Yao, Y.Q. (2009). Differential expression profile of microRNAs in human placentas from preeclamptic pregnancies vs normal pregnancies. AJOG 200, 661.e1-661.e7.